(Q37849131)

24 August 2017

1 reference

title

Immunoconjugates against solid tumors: mind the gap. (English)

1 reference

24 August 2017

A D Ricart

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

2 March 2011

1 reference

Clinical Pharmacology & Therapeutics

24 August 2017

published in

1 reference

24 August 2017

volume

89

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

513-523

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Escherichia coli secretion of an active chimeric antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Phage antibodies: filamentous phage displaying antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Assembly of a functional immunoglobulin Fv fragment in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Pharmacokinetics and biodistribution of genetically engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Anti-CD30 diabody-drug conjugates with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Technology insight: cytotoxic drug immunoconjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Radioimmunotherapy of prostate cancer: does tumor size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Development trends for therapeutic antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

Pilot trial of murine monoclonal antibodies in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Barriers to drug delivery in solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Radioimmunotherapy--hot new treatment for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.8

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.8

1 reference

24 August 2017

1 reference